351 Innate lymphoid cells in the blood of untreated and dupilumab-treated patients with atopic dermatitis

Abstract

To investigate the driving force behind the increase of innate lymphoid cells (ILCs) in atopic dermatitis (AD) skin, we numerically and phenotypically compared ILC populations in the blood of untreated AD patients (AD-U), long term (≥16 weeks) dupilumab-treated AD patients (AD-D) and healthy controls (HC). PBMCs were isolated from clinically active AD patients (median age: 32.2 years; n=9), dupilumab-treated AD patients (median age: 33.3 years; n=6) and healthy individuals (median age:28.3 years; n=10), immunostained with a panel of subset-characterising antibodies and analysed with a BD FACSAria III sorter.